Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. Presented recently at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented two abstracts related to their novel immunotherapy, pelareorep, an intravenously delivered immunotherapeutic agent. "The first abstract outlines the design of a new GOBLET PDAC cohort that could significantly expand the potential of the company's pancreatic cancer program," said Dr. Matt C ...